Table 3.

The summary of meta-analysis of clinicopathological parameters associated with cyclin B1, and B2 expression.

Target molecule	Clinicopathological parameter	Number of studies	Odds ratio	OR in favor of	Confidence interval	P value of OR	I 2	P value of I2
Cyclin B1	Age	2	0.61	Younger age	0.31–1.19	.15	0 %	.83
	Tumor stage	2	0.78	Lower stage	0.29–2.12	.63	38 %	.2
	Tumor grade	4	1.29	Higher grade	0.42–3.97	.66	67 %	.03
	Histologic type	2	0.68	Other types	0.24–1.91	.47	0 %	.67
	Estrogen receptor	2	1.12	ER positive	0.51–2.43	.78	2 %	.31
Cyclin B2	Age	2	0.64	Younger age	0.34–1.2	.16	0 %	.59
	Tumor size	2	1.81	Larger size	0.74–4.45	.19	30 %	.23
	Tumor grade	2	0.74	Lower grade	0.39–1.41	.36	7 %	.3
	Node status	2	0.71	Node negative	0.38–1.33	.29	0 %	.63
Cyclin B1 and B2	Age	4	0.62	Younger age	0.39–0.99	.04	0 %	.95
	Tumor grade	6	1.02	Tumor grade	0.55–1.89	.95	56 %	.05

OR: odds ratio.